Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $75.8 million Upfront Cash: Undisclosed
Deal Type: Funding June 09, 2020
The funding is provided for over five years to support a 540-patient Phase 2 study of CT1812 in individuals with early Alzheimer’s disease. The study will be conducted in conjunction with the Alzheimer’s Clinical Trials Consortium (ACTC).